Back to search results

DISCOVERY Study: Understanding Type 2 Diabetes Risk in Youth

The DISCOVERY study is looking for young people aged 8 to 15 who are at risk of developing type 2 diabetes (T2D). This observational study aims to understand what factors lead to T2D in youth, especially during puberty. Researchers will follow participants for an average of 2.5 years to see how their bodies change and if they develop T2D. This information will help design better ways to prevent and treat T2D in young people in the future. You may be eligible if you are overweight or obese, and meet specific age and puberty stage criteria.

Study design
This is an observational study planning to enroll 3600 participants. It aims to understand the natural progression of type 2 diabetes risk in youth.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed through study completion, which is an average of 2.5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06525259

DISCOVERY of Risk Factors for Type 2 Diabetes in Youth

Recruiting
Not specifiedAges 8–15Observational
George Washington University
~3,600 participants
Updated 2026-05-07 on ClinicalTrials.gov

At a glance

Recruiting sites
20 of 20 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Type 2 diabetes
Measured over Through study completion, an average of 2.5 years

Conditions

Diabetes Mellitus Type 2, Childhood-Onset

Explore related trials

Type 2 Diabetes Mellitus

Where it's being run

20 sites across 14 states
New York4
Arizona2
North Carolina2
Ohio2
Alabama1
California1
Colorado1
Florida1

Who to contact

Barbara Braffett, PhD
[email protected]
3018819260
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Overweight or obesity with BMI ≥85th percentile
Age 8-13 year for girls, 9-15 year for boys (inclusion younger for girls as puberty tends to start a year earlier in girls)
Tanner Stage 2, 3, or 4
Elevated HbA1c 5.5-6.4%

Exclusion

Diabetes based on history, or HbA1c ≥6.5% in the medical record or at screening
Unable/unwilling to provide consent/participate fully
Conditions predisposing to diabetes or altering the trajectory of puberty
Medications affecting glucose dynamics during the screening and enrollment period
Prior treatment with insulin
Use of glucagon-like peptide-1 (GLP-1) receptor agonist or any weight loss medications in the 6 weeks prior to enrollment
Planning treatment with glucagon-like peptide-1 (GLP-1) receptor agonist or any weight loss medications
Use of metformin or any glucose lowering medication for a reason other than treatment of diabetes (e.g., for PCOS) in the 6 weeks prior to enrollment
Planning treatment with metformin or any glucose lowering medication or planning to use such medications for a reason other than treatment of diabetes (e.g., for PCOS)
Known syndromic/monogenic obesity
Blood disorders impacting HbA1c (e.g., anemia, hemoglobin variants)
Major systemic organ disease
History of bariatric surgery or currently planning bariatric surgery
Current pregnancy or currently planning pregnancy
Use of GnRH agonist, estrogen, or testosterone
Individuals who do not speak English or Spanish, given validation of the questionnaires to be utilized

What this trial measures

  • Type 2 diabetesThrough study completion, an average of 2.5 years

    Development of type 2 diabetes, as defined by a hemoglobin A1c (HbA1c) ≥6.5% at an annual or mid-year visit followed by a confirmatory HbA1c ≥6.5% collected within 2 weeks of the first value.